前立腺肥大症治療薬の世界市場レポート 2024年

前立腺肥大症治療薬市場規模は近年力強く成長しています。2023年の40億2,000万米ドルから2024年には43億1,000万米ドルへと、CAGR7.1％で拡大します。過去の期間に見られた成長は、人口の高齢化、前立腺肥大症に対する意識の高まり、薬物療法の進歩、医療サービスへのアクセスの改善など、いくつかの要因によるものです。これらの要因が、この疾患に対する治療法の実績に寄与しています。

前立腺疾患の有病率の高まりは、前立腺肥大症治療薬市場の今後の成長を牽引すると予想されます。前立腺疾患は、膀胱のすぐ下に位置する男性生殖器官である前立腺に影響を及ぼす様々な病状を包含します。前立腺肥大症治療薬（BPH）は、前立腺疾患に伴う排尿症状を管理・緩和する上で重要な役割を果たしています。これらの薬剤は、前立腺の肥大を抑え、尿の流れを改善することで症状を緩和します。例えば、米国の医療機関であるハーバード・メディカル・スクールが2021年2月に発表した報告によると、60歳までに男性の50％が前立腺肥大を経験し、この割合は85歳までに90％に増加することが明らかになっています。したがって、前立腺疾患の有病率の増加が前立腺肥大症治療薬市場の成長を促進しています。

2023年の前立腺肥大症治療薬市場で最大の地域は北米です。中東は前立腺肥大症治療薬市場で最も急成長している地域になると予測されています。前立腺肥大症治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 前立腺肥大症治療薬市場の特徴

第3章 前立腺肥大症治療薬の市場動向と戦略

第4章 前立腺肥大症治療薬市場-マクロ経済シナリオ

第5章 世界の前立腺肥大症治療薬市場規模と成長

• 世界の前立腺肥大症治療薬市場の促進要因と抑制要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界の前立腺肥大症治療薬の市場規模実績と成長、2018～2023年
• 世界の前立腺肥大症治療薬市場規模と成長予測、2023～2028年、2033年

第6章 前立腺肥大症治療薬市場セグメンテーション

• 世界の前立腺肥大症治療薬市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• アルファブロッカー
• 5-αリダクターゼ阻害剤
• ホスホジエステラーゼ-5阻害剤
• その他のタイプ
• 世界の前立腺肥大症治療薬市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の前立腺肥大症治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• 小売薬局
• その他のエンドユーザー

第7章 前立腺肥大症治療薬市場の地域と国分析

• 世界の前立腺肥大症治療薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の前立腺肥大症治療薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋の前立腺肥大症治療薬市場

第9章 中国の前立腺肥大症治療薬市場

第10章 インドの前立腺肥大症治療薬市場

第11章 日本の前立腺肥大症治療薬市場

第12章 オーストラリアの前立腺肥大症治療薬市場

第13章 インドネシアの前立腺肥大症治療薬市場

第14章 韓国の前立腺肥大症治療薬市場

第15章 西欧の前立腺肥大症治療薬市場

第16章 英国の前立腺肥大症治療薬市場

第17章 ドイツの前立腺肥大症治療薬市場

第18章 フランスの前立腺肥大症治療薬市場

第19章 イタリアの前立腺肥大症治療薬市場

第20章 スペインの前立腺肥大症治療薬市場

第21章 東欧の前立腺肥大症治療薬市場

第22章 ロシアの前立腺肥大症治療薬市場

第23章 北米の前立腺肥大症治療薬市場

第24章 米国の前立腺肥大症治療薬市場

第25章 カナダの前立腺肥大症治療薬市場

第26章 南米の前立腺肥大症治療薬市場

第27章 ブラジルの前立腺肥大症治療薬市場

第28章 中東の前立腺肥大症治療薬市場

第29章 アフリカの前立腺肥大症治療薬市場

第30章 前立腺肥大症治療薬市場の競合情勢と企業プロファイル

• 前立腺肥大症治療薬市場の競合情勢
• 前立腺肥大症治療薬市場企業プロファイル
  • Allergan Inc.
  • Astellas Pharma Inc.
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Limited

第31章 前立腺肥大症治療薬の世界の市場競合ベンチマーキング

第32章 世界の前立腺肥大症治療薬市場の競合ダッシュボード

第33章 前立腺肥大症治療薬市場における主要な合併と買収

第34章 前立腺肥大症治療薬市場の将来展望と可能性分析

第35章 付録

“Drugs For Benign Prostatic hypertrophy Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drugs for benign prostatic hypertrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drugs for benign prostatic hypertrophy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The drugs for benign prostatic hypertrophy market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Alpha Blocker; 5-alpha Reductase Inhibitor; Phosphodiesterase-5 Inhibitor; Other Types
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users
• Companies Mentioned: Allergan Inc.; Astellas Pharma Inc.; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Teva Pharmaceutical Industries Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Benign prostatic hypertrophy drugs are used to treat enlarged prostate glands by relaxing the muscles in the bladder neck and the muscle fibers in the prostate, thereby facilitating easier urination. Benign prostatic hypertrophy is a condition commonly observed in men over the age of 50.

The primary categories of drugs used for benign prostatic hypertrophy include alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other medications. Alpha-blockers, also known as blockers or adrenoreceptor antagonists, are a type of pharmaceutical drug that functions by blocking adrenergic receptors. These drugs are used in various sectors, including hospital pharmacies, retail pharmacies, and others, and they are distributed through a range of channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.02 billion in 2023 to $4.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth observed during the historical period can be attributed to several factors, including the aging population, heightened awareness of benign prostatic hypertrophy, advancements in drug therapies, and improved access to healthcare services. These factors have contributed to the historical growth of treatments for this condition.

The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.45 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The anticipated growth in the forecast period can be attributed to several factors, including the expansion of emerging markets, the development of new drugs, heightened awareness and education about benign prostatic hypertrophy, and regulatory approvals for treatments. Prominent trends in the forecast period encompass the adoption of minimally invasive treatments, the practice of personalized medicine, the use of combination therapies, a focus on patient-centered care, the integration of telemedicine and digital health solutions, and ongoing research and development efforts in the field.

The global growth in the male geriatric population is a key driver of the drugs for benign prostatic hypertrophy market since this condition is commonly observed in men aged 50 and above. As an example, in October 2022, the World Health Organization, a US-based specialized health agency, reported that by 2030, an estimated 1 in 6 individuals globally would be 60 years or older, and this figure is projected to increase to 2.1 billion elderly individuals by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia (BPH) affects approximately 50% of men aged between 51 and 60 years, and this percentage rises to as high as 90% among men aged over 80 years.

The growing prevalence of prostate diseases is expected to drive the future growth of the drugs for benign prostatic hypertrophy market. Prostate diseases encompass various medical conditions that impact the prostate gland, a male reproductive organ situated just below the bladder. Drugs for benign prostatic hypertrophy (BPH) play a critical role in managing and mitigating urinary symptoms associated with prostate diseases. These medications provide relief by reducing the enlargement of the prostate gland and improving urine flow. For instance, a report from the Harvard Medical School, a US-based medical institution, in February 2021, revealed that by the age of 60, 50% of men will experience prostate enlargement, and this proportion increases to 90% by the age of 85. Therefore, the increased prevalence of prostate diseases is propelling the growth of the drugs for benign prostatic hypertrophy market.

The increasing adoption of minimally invasive surgeries, driven by technological advancements, is a factor restraining the growth of the Benign Prostatic Hyperplasia drugs market. Minimally invasive surgeries typically result in less pain and are often performed on an outpatient basis, negating the need for Benign Prostatic Hyperplasia drugs. This serves as a limitation on the market. Some of the minimally invasive surgical approaches used for Benign Prostatic Hyperplasia treatment include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT), and transurethral needle ablation (TUNA).

The combination drugs are gaining prominence in the treatment of benign prostatic hypertrophy due to their enhanced effectiveness and disease progression prevention. Combination drugs incorporate two or more active pharmaceutical ingredients (APIs) within a single dosage form. These drugs reduce the risk of drug resistance, lead to fewer side effects, and have a lower treatment failure rate. For instance, Duodart, which combines dutasteride and tamsulosin hydrochloride, is increasingly prescribed for Benign Prostatic Hypertrophy treatment.

Major companies in the drugs for benign prostatic hypertrophy market are concentrating on the introduction of innovative medications like Entadfi to maximize their market revenue. Entadfi is a prescription medicine designed to address the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. For example, in December 2021, Veru Inc., a US-based biotechnology company, obtained approval from the United States Food and Drug Administration (FDA) for Entadfi. This prescription medication is intended for the treatment of BPH symptoms in men with an enlarged prostate for a duration of up to 26 weeks. The approval of Entadfi was based on a randomized, double-blind, placebo-controlled phase 3 study that assessed the efficacy and safety of tadalafil in combination with finasteride in 696 men. Entadfi is provided in capsule form, containing a combination of finasteride 5mg and tadalafil 5mg, available in 30- or 90-count bottles.

Major companies operating in the drugs for benign prostatic hypertrophy market include Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International PLC, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2023. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the drugs for benign prostatic hypertrophy market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Drugs For Benign Prostatic hypertrophy Market Characteristics

3. Drugs For Benign Prostatic hypertrophy Market Trends And Strategies

4. Drugs For Benign Prostatic hypertrophy Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Drugs For Benign Prostatic hypertrophy Market Size and Growth

• 5.1. Global Drugs For Benign Prostatic hypertrophy Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Drugs For Benign Prostatic hypertrophy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Drugs For Benign Prostatic hypertrophy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Drugs For Benign Prostatic hypertrophy Market Segmentation

• 6.1. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Alpha Blocker
• 5-alpha Reductase Inhibitor
• Phosphodiesterase-5 Inhibitor
• Other Types
• 6.2. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other End-Users

7. Drugs For Benign Prostatic hypertrophy Market Regional And Country Analysis

• 7.1. Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market

• 8.1. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Drugs For Benign Prostatic hypertrophy Market

• 9.1. China Drugs For Benign Prostatic hypertrophy Market Overview
• 9.2. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Drugs For Benign Prostatic hypertrophy Market

• 10.1. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Drugs For Benign Prostatic hypertrophy Market

• 11.1. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.2. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Drugs For Benign Prostatic hypertrophy Market

• 12.1. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Drugs For Benign Prostatic hypertrophy Market

• 13.1. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Drugs For Benign Prostatic hypertrophy Market

• 14.1. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.2. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Drugs For Benign Prostatic hypertrophy Market

• 15.1. Western Europe Drugs For Benign Prostatic hypertrophy Market Overview
• 15.2. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Drugs For Benign Prostatic hypertrophy Market

• 16.1. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Drugs For Benign Prostatic hypertrophy Market

• 17.1. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Drugs For Benign Prostatic hypertrophy Market

• 18.5. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Drugs For Benign Prostatic hypertrophy Market

• 19.9. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Drugs For Benign Prostatic hypertrophy Market

• 20.13. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Drugs For Benign Prostatic hypertrophy Market

• 21.1. Eastern Europe Drugs For Benign Prostatic hypertrophy Market Overview
• 21.2. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Drugs For Benign Prostatic hypertrophy Market

• 22.1. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Drugs For Benign Prostatic hypertrophy Market

• 23.1. North America Drugs For Benign Prostatic hypertrophy Market Overview
• 23.2. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Drugs For Benign Prostatic hypertrophy Market

• 24.1. USA Drugs For Benign Prostatic hypertrophy Market Overview
• 24.2. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Drugs For Benign Prostatic hypertrophy Market

• 25.1. Canada Drugs For Benign Prostatic hypertrophy Market Overview
• 25.2. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Drugs For Benign Prostatic hypertrophy Market

• 26.1. South America Drugs For Benign Prostatic hypertrophy Market Overview
• 26.2. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Drugs For Benign Prostatic hypertrophy Market

• 27.1. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Drugs For Benign Prostatic hypertrophy Market

• 28.1. Middle East Drugs For Benign Prostatic hypertrophy Market Overview
• 28.2. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Drugs For Benign Prostatic hypertrophy Market

• 29.1. Africa Drugs For Benign Prostatic hypertrophy Market Overview
• 29.2. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape And Company Profiles

• 30.1. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape
• 30.2. Drugs For Benign Prostatic hypertrophy Market Company Profiles
  • 30.2.1. Allergan Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Astellas Pharma Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Boehringer Ingelheim International GmbH
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. GlaxoSmithKline plc
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Teva Pharmaceutical Industries Limited
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Drugs For Benign Prostatic hypertrophy Market Competitive Benchmarking

32. Global Drugs For Benign Prostatic hypertrophy Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market

34. Drugs For Benign Prostatic hypertrophy Market Future Outlook and Potential Analysis

• 34.1 Drugs For Benign Prostatic hypertrophy Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Drugs For Benign Prostatic hypertrophy Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Drugs For Benign Prostatic hypertrophy Market In 2028 - Growth Strategies
• 34.3.1 Market Trend Based Strategies
• 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer